cushing’s syndrome is a rare endocrine disease characterized by hypercortisolemia caused by excess acth secreted by the pituitary. distinguishing pituitary sources from the ectopic sources of acth is challenging because of the limited accuracy of noninvasive assays. the test that offers the highest sensitivity and specificity is bilateral inferior petrosal sinus sampling (bipss). in patients wi...

The management of pituitary adenomas entails a multidisciplinary approach that involves neurosurgeons, endocrinologists, and radiation oncologists. Traditionally, the treatment included medical management, surgery (transsphenoidal microsurgical resection and transcranial approaches), and conventional fractionated radiotherapy. Stereotactic radiosurgery, through the various competing radiosurgic...

The occurrence of peroxisome proliferator-activated receptors gamma (PPARγ) was investigated in 51 human pituitary adenomas and in 6 non-tumoral human pituitary tissue samples. Moreover, the correlation between PPARγ and the proliferating cells nuclear antigen (PCNA) immunocytochemical proliferation marker was evaluated. The receptors and PCNA were detected by immunohistochemical methods using ...

PURPOSE Hypothalamic or locally produced growth factors and cytokines control pituitary development, functioning, and cell division. We evaluated the expression of the chemokine stromal cell-derived factor 1 (SDF1) and its receptor CXCR4 in human pituitary adenomas and normal pituitary tissues and their role in cell proliferation. EXPERIMENTAL DESIGN The expression of SDF1 and CXCR4 in 65 hum...

Pituitary tumors represent the most common intracranial neoplasms accompanying serious morbidity through mass effects and inappropriate secretion of pituitary hormones. Understanding the etiology of pituitary tumorigenesis will facilitate the development of satisfactory treatment for pituitary adenomas. Although the pathogenesis of pituitary adenomas is largely unknown, considerable evidence in...

OBJECT Pituitary adenomas are very common neoplasms, constituting between 10 and 20% of all primary brain tumors. Historically, the treatment armamentarium for pituitary adenomas has included medical management, microsurgery, and fractionated radiotherapy. More recently, radiosurgery has emerged as a viable treatment option. The goal of this research was to define more fully the efficacy, safet...

BACKGROUND/AIMS Although magnetic resonance imaging (MRI) is a good visual modality for the evaluation of pituitary lesions, it has limited value in the diagnosis of mixed nodules and some cystic lesions. We evaluated the usefulness of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) for patients with pituitary lesions. METHODS (18)F-FDG PET and MRI were performed simultaneousl...

Clinically nonfunctioning pituitary adenomas are benign neoplasms comprising approximately 25-30% of pituitary tumors. Little is known about the pathogenesis of pituitary neoplasia. Clonal analysis allows one to make the important distinction between a polyclonal proliferation in response to a stimulatory factor versus a monoclonal expansion of a genetically aberrant cell. We investigated the c...

BACKGROUND The purpose of this study was to (1) identify specific miRNAs in growth hormones (GH)-secreting pituitary adenomas; (2) determine the relationship between the expression of these miRNAs and tumor size, somatostatin analogs treatment, and responsiveness to somatostatin analogs (SSA). METHODS Fifteen GH-secreting adenomas patients were treated with lanreotide for 4 months before surg...

Male rat pituitary glands, diethylstilbestrol (DES)-induced rat pituitary tumors and 12 human pituitary adenomas were immunostained with antibodies raised against AT1 and AT2 angiotensin receptor proteins. Positive immunostaining of AT1 was observed in a subpopulation of anterior and intermediate pituitary lobe cells as well as in some nerve endings of the neurohypophysis. In the DES-induced ra...